(Q38079518)

28 August 2017

title

Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer (English)

1 reference

28 August 2017

1 reference

1 reference

Cindy L O'Bryant

1

1 reference

28 August 2017

Sarah D Wenger

series ordinal

2

1 reference

28 August 2017

Miryoung Kim

series ordinal

3

1 reference

28 August 2017

Lisa A Thompson

series ordinal

4

1 reference

28 August 2017

language of work or name

English

0 references

publication date

5 February 2013

1 reference

Annals of Pharmacotherapy

28 August 2017

published in

1 reference

28 August 2017

volume

47

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

189-197

1 reference

Targeted therapy for NSCLC: ALK inhibition

28 August 2017

cites work

1 reference

Crizotinib: an anaplastic lymphoma kinase inhibitor

21 January 2018

1 reference

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities

21 January 2018

1 reference

Targeting anaplastic lymphoma kinase in lung cancer

21 January 2018

1 reference

New strategies for treatment of ALK-rearranged non-small cell lung cancers

21 January 2018

1 reference

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)

21 January 2018

1 reference

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

21 January 2018

1 reference

Crizotinib: in locally advanced or metastatic non-small cell lung cancer

21 January 2018

1 reference

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

21 January 2018

1 reference

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

21 January 2018

1 reference

Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.

21 January 2018

1 reference

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation

21 January 2018

1 reference

Inhibitors of anaplastic lymphoma kinase: a patent review

21 January 2018

1 reference

Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy

21 January 2018

1 reference

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

21 January 2018

1 reference

MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations

21 January 2018

1 reference

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib

21 January 2018

1 reference

Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1R002

1 reference

28 August 2017

1 reference